 |
 |
Thanks, Ray. The last paragraph of the game changers article briefly mentions Nilotinib/Tasigna and contains a link to an article on the Georgetown study. Rytary a game changer? I hope it will improve lives, but it seems like a reach to cast this as a breakthrough--especially when enterprising patients like John have figured out on their own how to fine-tune their dosage. Kathleen On 29 December 2015 at 19:06, Rayilyn Brown <[log in to unmask]> wrote: > http://www.medpagetoday.com/Neurology/ParkinsonsDisease/55449 > Ray > Rayilyn Brown > Past Director AZNPF > Arizona Chapter National Parkinson Foundation > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn